Ionis Pharmaceuticals, Inc. today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living with Dravet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results